Tuesday, December 14, 2010

Botox can turn Muscle into Fat

New research shows that long-term use of Botox can cause muscle wastage in areas of the body that were not injected.



Botox injectionPhoto: vancouverlaser/Flickr
Botox is known to hinder a person’s ability to experience emotions. It may also be the new weapon of choice for terrorists. And a new report out of Canada might give you one more reason to reconsider an injection. The Daily Mail reports that Botox injections may cause muscle to atrophy into fat, even in parts of the body not injected with the toxin.

Botox is a $1.3 billion-a-year industry that does not show any signs of slowing. Seen as a quick and easy option for people hoping to dull fine lines, it involves an injection or series of injections to slow down the wrinkling process. Essentially, the toxin paralyzes the muscles so they cannot contract. It is used on all parts of the face and the neck, generally focusing on the medial brow. The procedure lasts for around three to five months and costs roughly $400 or $500 a session.

Complications from Botox can include raised eyebrows and droopy eyelids. Now it seems that it may break down muscle mass in your face and other areas of the body. As the Daily Mail reports, researchers from the University of Calgary injected a group of rabbits with Botulinum A toxin for a six-month period. Botulinum A is the poisonous bacterium that causes botulism and is fatal in high doses. Researchers found that injected limbs lost as much as 50 percent of their muscle mass. They also discovered a loss of muscle mass in areas of the body not injected with the cosmetic toxin.

Rafael Fortuna was the lead author of the study. As he told the Daily Mail, “What we have shown is some muscle tissue is being replaced by fat. We were surprised by the degree of muscle loss and atrophy in the limb that was not injected with the Botulinum toxin. I think it's fair to say that the paper raises some important questions about the long-term therapeutic use of Botox, especially with children and adolescents.”
                                                                
The New York Times reports that the FDA already requires that Botox carry warning labels that the toxin can spread to other parts of the body, and that it may initiate problems with breathing and swallowing. While these issues have occurred in patients who have received too large doses, the FDA nonetheless also requires doctors administering Botox to provide letters warning patients of the risks.

Wednesday, December 8, 2010

What is ageLOC?

what is ageloc?

target

ageLOC Science

The secret of youth: ageLOC targets the ultimate sources of aging to preserve the look of youth and reverse the appearance of aging.

arNOX and Age

Scientists have discovered that for most people, arNOX activity starts to increase during the “aging” years, beginning sometime during the mid-thirties and exponentially increasing for the next few decades. Studies have also shown that a person’s arNOX activity is not triggered by sun exposure, providing further evidence that increased arNOX activity is an identified source of internal aging.

arNOX and Appearance

In a study conducted at Stanford University, results indicated that people with high levels of the arNOX aging enzyme can appear on average seven years older than their biological age, while those with low levels can appear an average of seven years younger.

Stanford Study Shows

  • Individuals with high levels of arNOX are clinically graded to appear to be an average of seven years older than their actual age.
  • Individuals with low arNOX levels are clinically graded to appear to be an average of seven years younger than their actual chronological age.

arNOX Inhibition

Further studies showed that certain ingredients may prevent the expression of free radicals associated with the arNOX enzyme. This prevention may help slow the damage and signs of aging that come from accelerated free radical production.
This experiment shows how an ingredient inhibits arNOX enzyme activity (in an in vitro study).

The ageLOC Opportunity

By 2030 the number of people worldwide over the age of 60 is expected to reach more than one billion. By 2015, the anti-aging industry is expected to grow 76 percent in the United States, 73 percent in Japan, and 82 percent in the Asia-Pacific region.
The rise of aging consumers in most developed markets presents a remarkable marketing opportunity for those in the anti-aging industry. The demand for products that help to diminish or even turn around the aging process is high. The potential for growth in the anti-aging market is not only expected to skyrocket, it’s here for the long term.
Building on this global anti-aging megatrend, Nu Skin delivers ageLOC. ageLOC serves as a powerful platform for Nu Skin distributors as they continue to benefit from significant social and economic megatrends, including the growing aging population. Additionally, the economic environment bodes well for Nu Skin’s direct selling business model as Nu Skin offers an attractive option for those who need to supplement or replace their income in today’s harsh economy.
“Nu Skin continues to stay relevant by marketing innovative and scientifically validated products, as well as by paying the highest percentage of revenue in distributor commissions of all direct selling companies listed on the New York Stock Exchange,” said Ashok Pahwa, chief marketing officer at Nu Skin. “That is especially meaningful considering the fact that 2008 was the largest revenue year in Nu Skin’s 25-year history with $1.25 billion in sales.”